**Table 1: Baseline Characteristics**

|  |  |
| --- | --- |
| Characteristics | No. of patients n (%) |
| Age <15 years | **21 (13)** |
| Median Age | **30 years** |
| Gender (Male/Female) | **99/66(60/40)** |
| Localised disease | **112 (68%)** |
| Extremities as primary site | **123 (75%)** |
| Localised disease with extremities as primary site | **72(44%)** |
| Primary tumor size >5 CM | **72(44%)** |
| Localised disease with Primary tu  mor size >5 CM | **49 (30%)** |
| Underwent Surgery | **98 (59%)** |
| Radiotherapy | **91(55%)** |
| Chemotherapy | **119 (72%)** |

**Table 2: Significant Adverse events**

|  |  |
| --- | --- |
| Grade 3/4 Adverse event, n (%) | n (%) |
| Anemia | 33 (28) |
| Neutropenia | 75(63%) |
| Thrombocytopenia | 45(38) |
| Febrile Neutropenia | 47 (35) |
| Transaminitis | 5 (4) |
| Nausea/Vomiting | 21 (18) |
| Fatigue | 4 (3) |
| Diarrhea | 6 (5) |
| Oral Mucositis | 4 (3) |
| Heart failure | 0 (0) |

**Table 3: Survival Analysis**

|  |  |  |
| --- | --- | --- |
|  | Overall | Median Survival  (in Months) (95% Confidence Interval) |
|
| Overall Cohort (n=165) | OS | NE |
| EFS | 18 (15-21) |
| Metastatic Cohort (n=53) | OS | 60 (26-94) |
| EFS | 10 (6-14) |
| Localised Cohort (n=112) | OS | NE |
| EFS | 25 (17-33) |

\*NE: - Not Estimable \*\*n: - No. of Patient

\*\*\*OS: - Overall survival \*\*\*\*EFS: - Event Free Survival

**Table 4: Survival Probability at 24, 36, 60 Months**

|  |  |  |  |
| --- | --- | --- | --- |
|  | | Time (in Months) | Survival Probability (95% Confidence Interval) |
| Overall Cohort (n=165) | OS | 24 | 84% (78.2 - 90.3) |
| OS | 36 | 80% (73.5 - 87.3) |
| OS | 60 | 75% (67.3 - 83.5) |
| EFS | 24 | 37.6% (30.9 - 45.7) |
| EFS | 36 | 28.5% (22.4 - 36.3) |
| EFS | 60 | 24.2% (18.5 - 31.7) |
| Metastatic Cohort (n=53) | OS | 24 | 69.7% (56.3 - 86.2) |
| OS | 36 | 60.7% (45.5 - 80.8) |
| OS | 60 | 40.4% (20.6 - 79.4) |
| EFS | 24 | 9.4% (4.1 - 21.7) |
| EFS | 36 | 3.8% (1 - 14.7) |
| EFS | 60 | 1.9% (0.3 - 13.1) |
| Localised Cohort (n=112) | OS | 24 | 89.3% (83.5 - 95.5) |
| OS | 36 | 86.9% (80.5 - 93.9) |
| OS | 60 | 83.9% (76.5 - 91.9) |
| EFS | 24 | 50.9% (42.4 - 61) |
| EFS | 36 | 40.2% (32.1 - 50.4) |
| EFS | 60 | 34.8% (27 - 44.9) |